Heart failure & cardiomyopathies
Characterization of Serum Phosphate Levels Over Time with Intravenous Ferric Carboxymaltose Versus Placebo as Treatment for Heart Failure with Reduced Ejection Fraction and Iron Deficiency: An Exploratory Prospective Substudy From HEART-FID
Study context
- Population
- Ambulatory patients with heart failure with reduced ejection fraction (HFrEF) and iron deficiency
- Participants
- 133 patients
- Comparison
- Ferric carboxymaltose (FCM) vs placebo
- FCMn = 62
- Placebon = 71reference
Methodological detailspre-specified substudy, prospective, double-blind, placebo-controlled, exploratory
- Pre-specified substudy
- Prospective
- Double-blind
- Placebo-controlled
- Exploratory
Primary result
As reported in the abstract
Serum phosphate
- FCM: mean change in phosphate at nadir (day 21)
- −0.36 ± 0.27 mmol/L
- FCM: moderate-to-severe hypophosphataemia
- 28 (51%)
Safety
- No serious adverse events associated with hypophosphataemia reported
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Characterization of Serum Phosphate Levels Over Time with Intravenous Ferric Carboxymaltose Versus Placebo as Treatment for Heart Failure with Reduced Ejection Fraction and Iron Deficiency: An Exploratory Prospective Substudy From HEART-FID. Eur J Heart Fail. Published 19 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →